|
|
Exchange: |
Nasdaq National Market |
Security
Type: |
Common |
Shares
Out: |
66,921,000 |
Market
Cap: |
2.84(B) |
Last
Volume: |
1,212,774 |
Avg
Vol: |
1,001,263 |
52
Week Range: |
$38.26 - $89.25 |
|
Level
I Sector: |
Health Care |
Level
II Sector: |
Drugs |
Level
III Sector: |
Diagnostic Substances |
|
Member Indexes:
|
NASDAQ COMPOSITE |
|
NASDAQ NNM COMPOSITE |
|
Rankings:
|
Insider 3 Months : - |
Insider 6 Months : - |
Insider 3/6 Months : - |
|
Guru Rank Number : - |
Guru Rank Value : - |
Guru Occurances : - |
|
|
|
|
|
|
|
Company Profile QuidelOrtho is engaged in the development, manufacturing and marketing of diagnostic testing solutions. Co. provides diagnostic testing solutions under various brand names, including, among others, the following: Quidel®, QuickVue®, QuickVue+®, Sofia®, Triage®, Solana®, Virena®, MicroVue, Lyra®, FreshCells, D3®, FastPoint®, ReadyCells®, Super E-Mix, InflammaDry®, AdenoPlus®, ELVIRA®, ELVIS® and Thyretain®. Co.'s diagnostic testing solutions are separated into its four product categories: rapid immunoassay, cardiometabolic immunoassay, molecular diagnostic solutions and specialized diagnostic solutions.
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
3m +/-:
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
Actions:
|
|
|
B |
Buy |
S |
Sell |
OE |
Option
Exercised |
A |
Acquired |
D |
Disposed |
AB |
Automatic
Buy |
AS |
Automatic
Sell |
IO |
Initial
Ownership |
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
|
|
Summary (Direct Transactions Only) |
3 Months |
6 Months |
12 Months |
24 Months |
Total Shares Bought |
0 |
0 |
0 |
0 |
Total Buy Value |
$0 |
$0 |
$0 |
$0 |
Total People Bought |
0 |
0 |
0 |
0 |
Total Buy Transactions |
0 |
0 |
0 |
0 |
Total Shares Sold |
0 |
0 |
0 |
0 |
Total Sell Value |
$0 |
$0 |
$0 |
$0 |
Total People Sold |
0 |
0 |
0 |
0 |
Total Sell Transactions |
0 |
0 |
0 |
0 |
End Date |
2024-02-04 |
2023-11-03 |
2023-05-05 |
2022-05-05 |
|
Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
Bryant Douglas C |
President & CEO |
|
2021-02-15 |
4 |
D |
$227.97 |
$2,288,819 |
D/D |
(10,040) |
468,047 |
|
- |
|
Bryant Douglas C |
President & CEO |
|
2021-02-15 |
4 |
A |
$0.00 |
$0 |
D/D |
20,250 |
478,087 |
|
- |
|
Bujarski Robert Joseph |
Chief Operating Officer |
|
2021-02-15 |
4 |
D |
$227.97 |
$810,661 |
D/D |
(3,556) |
18,545 |
|
- |
|
Bujarski Robert Joseph |
Chief Operating Officer |
|
2021-02-15 |
4 |
A |
$0.00 |
$0 |
D/D |
7,172 |
22,101 |
|
- |
|
Gibson Karen |
SVP, Digital Health |
|
2021-02-15 |
4 |
D |
$227.97 |
$429,268 |
D/D |
(1,883) |
6,105 |
|
- |
|
Gibson Karen |
SVP, Digital Health |
|
2021-02-15 |
4 |
A |
$0.00 |
$0 |
D/D |
3,797 |
7,988 |
|
- |
|
Kroll Werner |
SVP, R&D |
|
2021-02-04 |
4 |
D |
$228.68 |
$501,267 |
D/D |
(2,192) |
8,225 |
|
- |
|
Kroll Werner |
SVP, R&D |
|
2021-02-04 |
4 |
A |
$0.00 |
$0 |
D/D |
4,268 |
10,417 |
|
- |
|
Bryant Douglas C |
President & CEO |
|
2021-02-03 |
4 |
D |
$236.85 |
$445,752 |
D/D |
(1,882) |
457,736 |
|
- |
|
Bryant Douglas C |
President & CEO |
|
2021-02-03 |
4 |
A |
$0.00 |
$0 |
D/D |
3,795 |
459,618 |
|
- |
|
Ferenczy William J. |
SVP, Cardio/Metabolic Unit |
|
2021-02-03 |
4 |
D |
$236.85 |
$53,528 |
D/D |
(226) |
4,888 |
|
- |
|
Ferenczy William J. |
SVP, Cardio/Metabolic Unit |
|
2021-02-03 |
4 |
A |
$0.00 |
$0 |
D/D |
653 |
5,114 |
|
- |
|
Steward Randall J |
Chief Financial Officer |
|
2021-02-03 |
4 |
D |
$236.85 |
$591,651 |
D/D |
(2,498) |
6,487 |
|
- |
|
Steward Randall J |
Chief Financial Officer |
|
2021-02-03 |
4 |
A |
$0.00 |
$0 |
D/D |
5,616 |
8,985 |
|
- |
|
Ranalli Tamara A. |
SVP, Molecular Bus. Unit |
|
2021-02-03 |
4 |
D |
$236.85 |
$34,343 |
D/D |
(145) |
9,302 |
|
- |
|
Ranalli Tamara A. |
SVP, Molecular Bus. Unit |
|
2021-02-03 |
4 |
A |
$0.00 |
$0 |
D/D |
593 |
9,447 |
|
- |
|
Russell Edward Keith |
SVP, Business Development |
|
2021-02-03 |
4 |
D |
$236.85 |
$136,189 |
D/D |
(575) |
18,276 |
|
- |
|
Russell Edward Keith |
SVP, Business Development |
|
2021-02-03 |
4 |
A |
$0.00 |
$0 |
D/D |
1,661 |
18,851 |
|
- |
|
Bujarski Robert Joseph |
Chief Operating Officer |
|
2021-02-03 |
4 |
D |
$236.85 |
$187,348 |
D/D |
(791) |
14,929 |
|
- |
|
Bujarski Robert Joseph |
Chief Operating Officer |
|
2021-02-03 |
4 |
A |
$0.00 |
$0 |
D/D |
1,661 |
15,720 |
|
- |
|
Gibson Karen |
SVP, Digital Health |
|
2021-02-03 |
4 |
D |
$236.85 |
$195,164 |
D/D |
(824) |
4,151 |
|
- |
|
Gibson Karen |
SVP, Digital Health |
|
2021-02-03 |
4 |
A |
$0.00 |
$0 |
D/D |
1,661 |
4,975 |
|
- |
|
Kroll Werner |
SVP, R&D |
|
2021-01-29 |
4 |
D |
$250.97 |
$382,980 |
D/D |
(1,526) |
6,149 |
|
- |
|
Kroll Werner |
SVP, R&D |
|
2021-01-29 |
4 |
A |
$0.00 |
$0 |
D/D |
2,970 |
7,675 |
|
- |
|
Gibson Karen |
SVP, Digital Health |
|
2021-01-29 |
4 |
D |
$250.97 |
$282,592 |
D/D |
(1,126) |
3,314 |
|
- |
|
1127 Records found
|
|
Page 7 of 46 |
|
|